Peter Stopfer

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Venues

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

British journal of clinical pharmacology

European journal of drug metabolism and pharmacokinetics

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

University of Regensburg (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Pharma GmbH and Co KG Biberach Jul 01 2004

Germany

Head of Global clin PK/PD :: Translational Medicine and Clinical Pharmacology

Education History

University of Regensburg Jul 01 2000 - Jul 01 2003

Germany

PHD :: Tumor Immunology

Publications

Arne Gessner, Martin F Fromm, Pia Wenisch, Markus R Heinrich, Peter Stopfer, Martin F Fromm, Fabian Müller
New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clinical pharmacology and therapeutics (2024)
Arne Gessner, Fabian Müller, Pia Wenisch, Markus R Heinrich, Jörg König, Peter Stopfer, Martin F Fromm
A metabolomic analysis of sensitivity and specificity of 23 previously proposed biomarkers for renal transporter-mediated drug-drug interactions. Clinical pharmacology and therapeutics (2023)
Fabian Müller, Kathrin Hohl, Sascha Keller, Sven Schmidt-Gerets, Birgit Deutsch, Annette Schuler-Metz, Martin F Fromm, Peter Stopfer, Arne Gessner
N 1 -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid. Clinical pharmacology and therapeutics (2023)
Fabian Müller, Kathrin Hohl, Sascha Keller, Sven Schmidt-Gerets, Birgit Deutsch, Annette Schuler-Metz, Martin F Fromm, Peter Stopfer, Arne Gessner
N 1 -methylnicotinamide as biomarker for MATE-mediated renal drug-drug interactions: impact of cimetidine, rifampin, verapamil, and probenecid. Clinical pharmacology and therapeutics (2023)
Sabrina T Wiebe, Thomas Giessmann, Kathrin Hohl, Sven Schmidt-Gerets, Edith Hauel, Alen Jambrecina, Kerstin Bader, Naoki Ishiguro, Mitchell E Taub, Ashish Sharma, Thomas Ebner, Gerd Mikus, Martin F Fromm, Fabian Müller, Peter Stopfer
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clinical pharmacokinetics 59 (12) (2021)
Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz, Thomas Ebner, Peter Stopfer, Claudia Dallinger
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical pharmacokinetics 58 (9) (2020)
Peter Stopfer, Thomas Giessmann, Kathrin Hohl, Sabine Hutzel, Sven Schmidt, Dietmar Gansser, Naoki Ishiguro, Mitchell E Taub, Ashish Sharma, Thomas Ebner, Fabian Müller
Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. British journal of clinical pharmacology 84 (9) (2018)
Peter Stopfer, Thomas Giessmann, Kathrin Hohl, Ashish Sharma, Naoki Ishiguro, Mitchell E Taub, Arvid Jungnik, Dietmar Gansser, Thomas Ebner, Fabian Müller
Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. European journal of drug metabolism and pharmacokinetics 43 (1) (2018)

Peter Stopfer.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Stopfer